Arming antibodies: prospects and challenges for immunoconjugates

[1]  William McBride,et al.  Pretargeting of Carcinoembryonic Antigen–Expressing Cancers with a Trivalent Bispecific Fusion Protein Produced in Myeloma Cells , 2005, Clinical Cancer Research.

[2]  W. Mcbride,et al.  Improving the Delivery of Radionuclides for Imaging and Therapy of Cancer Using Pretargeting Methods , 2005, Clinical Cancer Research.

[3]  S. Gambhir,et al.  Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging. , 2005, Cancer research.

[4]  A. Tolcher,et al.  Phase II trial of BB-10901 (huN901-DM1) given weekly for four consecutive weeks every 6 weeks in patients with relapsed SCLC and CD56-positive small cell carcinoma , 2005 .

[5]  Sur Sharma,et al.  Advances in antibody-directed enzyme prodrug therapy. , 2005, Current opinion in investigational drugs.

[6]  R. Lutz,et al.  HuC242-DM4, an antibody-maytansinoid conjugate with superior preclinical activity in human CanAg-positive tumor xenograft models in SCID mice , 2005 .

[7]  D. Farquhar,et al.  Generation of an intensely potent anthracycline by a monoclonal antibody-beta-galactosidase conjugate. , 2005, Bioconjugate chemistry.

[8]  D. Goldenberg,et al.  A phase I trial combining high-dose 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  Ana T Menendez,et al.  An anti-MUC1 antibody-calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance. , 2005, Bioconjugate chemistry.

[10]  Mohan Doss,et al.  Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. , 2005, Cancer research.

[11]  M. Linenberger,et al.  CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance , 2005, Leukemia.

[12]  Sanjiv S Gambhir,et al.  Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. , 2005, Cancer research.

[13]  G. Denardo,et al.  Characterization of site-specific ScFv PEGylation for tumor-targeting pharmaceuticals. , 2005, Bioconjugate chemistry.

[14]  C. Divgi,et al.  Current status of therapy of solid tumors. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  R. Wahl.  Tositumomab and (131)I therapy in non-Hodgkin's lymphoma. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  D. Goldenberg,et al.  Perspectives on cancer therapy with radiolabeled monoclonal antibodies. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  K. Chester,et al.  Engineered single chain antibody fragments for radioimmunotherapy. , 2004, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[18]  Suzanne V. Smith.  Technology evaluation: cantuzumab mertansine, ImmunoGen. , 2004, Current opinion in molecular therapeutics.

[19]  D. Carrasco,et al.  Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. , 2004, Blood.

[20]  Damon L. Meyer,et al.  Efficient Elimination of B-Lineage Lymphomas by Anti-CD20–Auristatin Conjugates , 2004, Clinical Cancer Research.

[21]  M. Silva,et al.  A Prostate-Specific Membrane Antigen-Targeted Monoclonal Antibody–Chemotherapeutic Conjugate Designed for the Treatment of Prostate Cancer , 2004, Cancer Research.

[22]  Damon L. Meyer,et al.  Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate , 2004, Clinical Cancer Research.

[23]  C. Meares,et al.  Converting weak binders into infinite binders. , 2004, Bioconjugate chemistry.

[24]  M. Brechbiel,et al.  A Single Treatment of Yttrium-90-labeled CHX-A″–C6.5 Diabody Inhibits the Growth of Established Human Tumor Xenografts in Immunodeficient Mice , 2004, Cancer Research.

[25]  N. Damle.  Tumour-targeted chemotherapy with immunoconjugates of calicheamicin , 2004, Expert opinion on biological therapy.

[26]  P. Trail,et al.  Monoclonal antibody mediated intracellular targeting of tallysomycin S(10b). , 2004, Bioorganic & medicinal chemistry letters.

[27]  Paul J Yazaki,et al.  Pilot Trial Evaluating an 123I-Labeled 80-Kilodalton Engineered Anticarcinoembryonic Antigen Antibody Fragment (cT84.66 Minibody) in Patients with Colorectal Cancer , 2004, Clinical Cancer Research.

[28]  R. Siegel,et al.  Yeast display of antibody fragments: a discovery and characterization platform. , 2004, Journal of immunological methods.

[29]  P. Frost,et al.  Antibody-Targeted Chemotherapy with the Calicheamicin Conjugate hu3S193-N-Acetyl γ Calicheamicin Dimethyl Hydrazide Targets Lewisy and Eliminates Lewisy-Positive Human Carcinoma Cells and Xenografts , 2004, Clinical Cancer Research.

[30]  J. Vose,et al.  Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma. , 2004, Blood.

[31]  Andreas Plückthun,et al.  In-vitro protein evolution by ribosome display and mRNA display. , 2004, Journal of immunological methods.

[32]  M. Rusckowski,et al.  Amplification targeting: a modified pretargeting approach with potential for signal amplification-proof of a concept. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[33]  M. Brechbiel,et al.  Antibody-targeted radiation cancer therapy , 2004, Nature Reviews Drug Discovery.

[34]  Neal Rosen,et al.  Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors , 2004, Nature Biotechnology.

[35]  S. Sharma,et al.  Modifying an immunogenic epitope on a therapeutic protein: a step towards an improved system for antibody-directed enzyme prodrug therapy (ADEPT) , 2004, British Journal of Cancer.

[36]  Serge Muyldermans,et al.  Efficient cancer therapy with a nanobody-based conjugate. , 2004, Cancer research.

[37]  Jinha M. Park,et al.  Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting. , 2004, Protein engineering, design & selection : PEDS.

[38]  Hongsheng Xie,et al.  Pharmacokinetics and Biodistribution of the Antitumor Immunoconjugate, Cantuzumab Mertansine (huC242-DM1), and Its Two Components in Mice , 2004, Journal of Pharmacology and Experimental Therapeutics.

[39]  Boris Gorovits,et al.  Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. , 2004, Blood.

[40]  G. Denardo,et al.  Production of Soluble ScFvs with C-Terminal-Free Thiol for Site-Specific Conjugation or Stable Dimeric ScFvs on Demand , 2004 .

[41]  S. Gambhir,et al.  Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications. , 2004, Protein engineering, design & selection : PEDS.

[42]  G. Denardo,et al.  Production of soluble ScFvs with C-terminal-free thiol for site-specific conjugation or stable dimeric ScFvs on demand. , 2004, Bioconjugate chemistry.

[43]  H. Borghaei,et al.  Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin). , 2004, Seminars in nuclear medicine.

[44]  A. Lawson,et al.  Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22 , 2004, Cancer Immunology, Immunotherapy.

[45]  G. Griffiths,et al.  Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  Paul J Yazaki,et al.  A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[47]  Sanjiv S Gambhir,et al.  124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[48]  I. Bernstein,et al.  Conditionally cleavable radioimmunoconjugates: a novel approach for the release of radioisotopes from radioimmunoconjugates. , 2003, Bioconjugate chemistry.

[49]  Damon L. Meyer,et al.  cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. , 2003, Blood.

[50]  P. Frost,et al.  Antibody-targeted chemotherapy with immunoconjugates of calicheamicin. , 2003, Current opinion in pharmacology.

[51]  S. Strand,et al.  Biotinylation, pharmacokinetics, and extracorporeal adsorption of humanized MAb 111In-MN14 using an avidin-affinity column in rats. , 2003, Cancer biotherapy & radiopharmaceuticals.

[52]  Damon L. Meyer,et al.  Development of potent monoclonal antibody auristatin conjugates for cancer therapy , 2003, Nature Biotechnology.

[53]  Gillian Payne.  Progress in immunoconjugate cancer therapeutics. , 2003, Cancer cell.

[54]  Dario Neri,et al.  Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[55]  A. Tolcher,et al.  Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  L. Zardi,et al.  Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED‐B domain of fibronectin , 2002, International journal of cancer.

[57]  E. Saad,et al.  Phase II Study of Dolastatin-10 as First-Line Treatment for Advanced Colorectal Cancer , 2002, American journal of clinical oncology.

[58]  C. Springer,et al.  A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours , 2002, British Journal of Cancer.

[59]  A. Wu,et al.  Reduction of kidney uptake in radiometal labeled peptide linkers conjugated to recombinant antibody fragments. Site-specific conjugation of DOTA-peptides to a Cys-diabody. , 2002, Bioconjugate chemistry.

[60]  P. Trail,et al.  Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. , 2002, Bioconjugate chemistry.

[61]  F. Garrido,et al.  Impaired surface antigen presentation in tumors: implications for T cell-based immunotherapy. , 2002, Seminars in cancer biology.

[62]  P. Trail,et al.  Synthesis of an immunoconjugate of camptothecin. , 2002, Bioorganic & medicinal chemistry letters.

[63]  I. Bernstein,et al.  An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. , 2002, Bioconjugate chemistry.

[64]  Irwin Hollander,et al.  Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. , 2002, Bioconjugate chemistry.

[65]  M. Linenberger,et al.  Mylotarg: antibody-targeted chemotherapy comes of age , 2001, Current opinion in oncology.

[66]  S. Gupta,et al.  Pretargeting with amplification using polymeric peptide nucleic acid. , 2001, Bioconjugate chemistry.

[67]  I. Bernstein,et al.  Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. , 2001, Blood.

[68]  E. Estey,et al.  Mylotarg™ (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation , 2001, Cancer.

[69]  G. Adams,et al.  High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. , 2001, Cancer research.

[70]  X. H. Chen,et al.  Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[71]  Y. Lin,et al.  Preclinical evaluation of a humanized NR-LU-10 antibody-streptavidin fusion protein for pretargeted cancer therapy. , 2001, Cancer biotherapy & radiopharmaceuticals.

[72]  J. Wong,et al.  Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and t84.66 minibody: comparison to radioiodinated fragments. , 2001, Bioconjugate chemistry.

[73]  P. Hudson,et al.  Ribosome display and affinity maturation: from antibodies to single V-domains and steps towards cancer therapeutics. , 2001, Journal of immunological methods.

[74]  Y. Lin,et al.  A tetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy. , 2000, Cancer research.

[75]  A. Wu,et al.  Designer genes: recombinant antibody fragments for biological imaging. , 2000, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[76]  H R Hoogenboom,et al.  Natural and designer binding sites made by phage display technology. , 2000, Immunology today.

[77]  J. Murray,et al.  Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  L. Chappell,et al.  Delivery of the alpha-emitting radioisotope bismuth-213 to solid tumors via single-chain Fv and diabody molecules. , 2000, Nuclear medicine and biology.

[79]  R. Begent,et al.  Catalytic activity of an in vivo tumor targeted anti‐CEA scFv::carboxypeptidase G2 fusion protein , 2000, International journal of cancer.

[80]  D. Fisher,et al.  Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results. , 2000, Cancer biotherapy & radiopharmaceuticals.

[81]  Andreas Plückthun,et al.  Stable one-step technetium-99m labeling of His-tagged recombinant proteins with a novel Tc(I)–carbonyl complex , 1999, Nature Biotechnology.

[82]  M. Walker,et al.  Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs. , 1999, Pharmacology & therapeutics.

[83]  I. Bernstein,et al.  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Selective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin Immunoconjugate , 2017 .

[84]  Y. Arano.  Strategies to reduce renal radioactivity levels of antibody fragments. , 1998, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[85]  J. Knipe,et al.  Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol), mitomycin C and doxorubicin. , 1998, Bioorganic & medicinal chemistry letters.

[86]  G. Dubowchik,et al.  Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin. , 1998, Bioorganic & medicinal chemistry letters.

[87]  S. Larson,et al.  Single chain antigen binding protein (sFv CC49) , 1997, Cancer.

[88]  N. Siemers,et al.  Construction, expression, and activities of L49-sFv-beta-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation. , 1997, Bioconjugate chemistry.

[89]  J. Knipe,et al.  Disposition of conjugate-bound and free doxorubicin in tumor-bearing mice following administration of a BR96-doxorubicin immunoconjugate (BMS 182248) , 1997, Cancer Chemotherapy and Pharmacology.

[90]  R. Hawkins,et al.  Clinical evidence of efficient tumor targetting based on single–chain Fv antibody selected from a combinatorial library , 1996, Nature Medicine.

[91]  P. Hand,et al.  Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins. , 1995, Cancer research.

[92]  J N Weinstein,et al.  Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[93]  M. Little,et al.  Bifunctional and multimeric complexes of streptavidin fused to single chain antibodies (scFv). , 1995, Journal of immunological methods.

[94]  C. Springer,et al.  Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates. , 1994, Methods and findings in experimental and clinical pharmacology.

[95]  H. Abderrahim,et al.  Antigen–specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs , 1994, Nature Genetics.

[96]  D. Huszar,et al.  Antigen-specific human antibodies from mice comprising four distinct genetic modifications , 1994, Nature.

[97]  P. Trail,et al.  Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. , 1993, Science.

[98]  J. Uhr,et al.  Immunotoxins: magic bullets or misguided missiles? , 1993, Trends in pharmacological sciences.

[99]  S. Denardo,et al.  Influence of a peptide linker on biodistribution and metabolism of antibody-conjugated benzyl-EDTA. Comparison of enzymatic digestion in vitro and in vivo. , 1992, Bioconjugate chemistry.

[100]  R. Jain.  Tumor physiology and antibody delivery. , 1990, Frontiers of radiation therapy and oncology.

[101]  E. Gautherot,et al.  In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[102]  R. Jain.  Tumor Physiology and Antibody Delivery1 , 1989 .

[103]  D. Newell,et al.  Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages. , 1988, Cancer research.

[104]  C. Meares,et al.  Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.